Compare PRMB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRMB | RYTM |
|---|---|---|
| Founded | 1955 | 2008 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.4B |
| IPO Year | N/A | N/A |
| Metric | PRMB | RYTM |
|---|---|---|
| Price | $18.23 | $102.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $29.27 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 5.3M | 657.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.97 | $47.98 |
| Revenue Next Year | $0.79 | $56.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.36 | $45.91 |
| 52 Week High | $35.85 | $122.20 |
| Indicator | PRMB | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 49.11 |
| Support Level | $18.66 | $95.44 |
| Resistance Level | $19.46 | $110.93 |
| Average True Range (ATR) | 0.62 | 5.61 |
| MACD | -0.16 | -0.53 |
| Stochastic Oscillator | 14.75 | 48.51 |
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.